Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Determinants of Vitamin K Metabolism

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sarah Booth, Tufts University
ClinicalTrials.gov Identifier:
NCT00336232
First received: June 12, 2006
Last updated: April 22, 2016
Last verified: April 2016

June 12, 2006
April 22, 2016
May 2006
July 2009   (final data collection date for primary outcome measure)
Plasma Phylloquinone [ Time Frame: 2 months ] [ Designated as safety issue: No ]
Plasma phylloquinone in response to phylloquinone depletion and repletion
  • Vitamin K (VK) status markers at VK depletion and repletion
  • Urinary excretion of VK metabolites at VK depletion and repletion
  • Bone turnover markers at VK depletion and repletion
Complete list of historical versions of study NCT00336232 on ClinicalTrials.gov Archive Site
Not Provided
  • Plasma triglyceride levels at VK depletion and repletion
  • Glucose metabolism measures at VK depletion and repletion
  • Mood assessment at VK depletion and repletion
Not Provided
Not Provided
 
Determinants of Vitamin K Metabolism
Dietary and Non-dietary Components of Vitamin K Metabolism
The purpose of this study is to learn how the body responds to different amounts of vitamin K in the diet in order to understand the roles that vitamin K may have in the body. We also need to determine if older adults need more or less vitamin K in their diet compared to younger adults in order to maintain normal body stores of vitamin K.
Vitamin K has a role in bone health, but little is known about vitamin K metabolism in aging and in maintenance of bone mass. The limited understanding of vitamin K metabolism impedes the establishment of dietary recommendations for vitamin K, and the interpretation of results from clinical trials on vitamin K supplementation and bone health of women in a narrow age group. This study is the first to assess the role of dietary and other factors that influence the response to vitamin K status and bone turnover to vitamin K depletion and repletion in adults. This study also compares the absorption efficiency and body retention of vitamin K relative to current vitamin K status. Men and women [21 younger (18-40y) and 21 older (55+y)] will participate in a 62-d metabolic study, with a 5d run-in period, followed by a 28d dietary vitamin K restriction period (10 ug/d), and ending with a 28d dietary vitamin K supplementation period (500 ug/d). Coagulation times will be monitored during the dietary restriction period. Serial measurements of vitamin K status markers and of bone turnover markers will show the response of vitamin K to dietary manipulation for both age groups under identically controlled dietary conditions. Deuterium-labeled vitamin K in collards will be used to compare the absorption of vitamin K during a vitamin K-deplete state to that of a vitamin K-replete state. Vitamin K is transported in triglyceride-rich lipoproteins, which may vary among individuals due to differences in adiposity and lipid homeostasis. Therefore, measurement of body composition by Dual Energy X-Ray Absorptiometry (DXA) and plasma lipids will provide insight into the role of lipids in absorption and transport of vitamin K. The findings of this study are critical for the interpretation of the epidemiologic and clinical data used to determine the protective role vitamin K may have in chronic disease prevention.
Interventional
Not Provided
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Aging
  • Osteoporosis
Drug: Vitamin K
phylloquinone (vitamin K1) 500 mcg daily in third month
Other Name: phylloquinone
Experimental: Diet Intervention
28 day diet low vitamin K, 28 day diet high vitamin K
Intervention: Drug: Vitamin K

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

Exclusion Criteria:

  • kidney, GI, or liver disease requiring treatment
  • prescribed osteoporosis medications in the previous 3 months
  • use of acid reducers more than twice per week
  • blood clotting disorder and/or abnormal clotting time
  • warfarin or anticoagulant use in the previous 12 months
  • diabetes
  • smoking
  • hormone therapy in the previous 3 months
  • oral contraceptive use in the previous 3 months; pregnancy
  • strict vegetarian diet
Both
18 Years to 90 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00336232
R01DK069341
No
Yes
Not Provided
Sarah Booth, Tufts University
Tufts University
Not Provided
Principal Investigator: Sarah L Booth, PhD Tufts Medical Center
Tufts University
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP